UK NEQAS For Antibiotic Assays
(Accredited by CPA (UK) Ltd., reference 025/0072)
ANNUAL
REPORT
April 2005 to March 2006
UK
NEQAS for Antibiotic Assays
BCARE
Southmead
Hospital
North
Bristol NHS Trust
Bristol
BS10 5NB
UK
Telephone
UK + (0)117 595 6214
Fax
UK + (0)117 959 3217
rhiannon.john@nbt.nhs.uk
www.ukneqasaa.win-uk.net
www.ukneqas.org.uk
The UK NEQAS for
Antibiotic Assays
The
Annual Report for April 2005 to March
2006
Alasdair MacGowan
- Organiser
Rhiannon John - Manager
Alan Davis - Distribution
Manager
This Annual
Report contains the most recent method, sub-method and laboratory performances
(in table form) by our participants for each antibiotic. These tables are separate links to this
short overview of the scheme. There is also a review of the communications
received from our members during the year. Further copies of this report, in
Word format, can be downloaded from www.ukneqasaa.win-uk.net. An up-to-date edition of The Participants’ Manual
can also be accessed and downloaded from the web-site too. For more general information about quality
assurance and all other UK NEQAS activities please go to www.ukneqas.org.uk.
The Quality Control Antibiotic Assay Distributions
Twelve batches
of quality control samples were sent out from April 2005 to March 2006. They
included amikacin (AMIK), gentamicin
(GENT), tobramycin (TOB) and vancomycin (VANC).
Flucytosine
(FLU) and netilmicin (NET)
were still distributed despite there being only a few returns for each analyte.
Due to the increase in monitoring in teicoplanin (TEIC) over the past few years this
antibiotic was added to the scheme in January 2005 and scoring commenced in
June 2005.
Antibiotics
not Scored
Netilmicin has ceased to
be available and over recent years we have had a declining number of returns
for this antibiotic. As the number of
participants has dropped below 12 we no longer score returns this antibiotic. Our new analyte, teicoplanin,
was scored from June 2005.
3 low
concentration samples were circulated (1 teicoplanin, 1 tobramycin
and 1 amikacin). None of these
distributions were scored as they were less than the concentration range for
most low concentration internal controls.
Scheme Participation
In total, 262 laboratories took part in the scheme.
Table 1 Participating Laboratories
|
Antibiotic |
UK |
Europe |
World |
Total |
|
Amikacin |
50 |
24 |
3 |
77 |
|
Flucytosine |
7 |
1 |
0 |
8 |
|
Gentamicin |
194 |
44 |
5 |
243 |
|
Netilmicin |
8 |
15 |
1 |
24 |
|
Teicoplanin |
7 |
9 |
0 |
16 |
|
Tobramycin |
64 |
27 |
2 |
93 |
|
Vancomycin |
167 |
45 |
5 |
217 |
|
All antibiotics |
201 |
55 |
6 |
262 |
In addition to labs registered with our scheme, we supplied antibiotics to the Heath Control scheme for their participating laboratories to assay.
During the distribution year 6 new laboratories joined and 2 laboratories resigned from the scheme.
Total Returns over the Distribution Year
Table 2 shows
the total number of registered participants for each distribution and each
antibiotic the number of returns made by participants, and the number of repeat
samples sent out to laboratories returning a result >30% away from the ALTM.
|
|
|
|
|
|
||
Table 2
Participant Returns per Distribution
|
|
Analyte |
||||||
|
|
Amik |
Flu |
Gent |
Net |
Teic |
Tob |
Vanc |
|
n= Dist |
|
|
|
|
|
|
|
|
Participants 1869 |
128 |
15 |
321 |
27 |
27 |
143 |
320 |
|
Returns |
101 |
11 |
281 |
14 |
25 |
123 |
276 |
|
Repeats |
0 |
0 |
2 |
0 |
1 |
1 |
10 |
|
Participants 1870 |
129 |
15 |
321 |
27 |
27 |
141 |
320 |
|
Returns |
101 |
10 |
265 |
13 |
20 |
122 |
275 |
|
Repeats |
0 |
0 |
2 |
0 |
0 |
4 |
2 |
|
Participants 1871 |
128 |
15 |
319 |
27 |
28 |
140 |
318 |
|
Returns |
102 |
9 |
276 |
15 |
24 |
121 |
272 |
|
Repeats |
0 |
0 |
0 |
0 |
0 |
2 |
1 |
|
Participants 1872 |
128 |
15 |
319 |
28 |
28 |
141 |
319 |
|
Returns |
101 |
10 |
273 |
15 |
24 |
120 |
264 |
|
Repeats |
1 |
0 |
9 |
1 |
0 |
0 |
1 |
|
Participants 1873 |
128 |
15 |
320 |
27 |
29 |
141 |
318 |
|
Returns |
100 |
8 |
271 |
13 |
23 |
94 |
268 |
|
Repeats |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Participants 1874 |
129 |
15 |
318 |
27 |
29 |
142 |
317 |
|
Returns |
92 |
9 |
267 |
14 |
23 |
118 |
257 |
|
Repeats |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Participants 1875 |
129 |
15 |
318 |
26 |
29 |
141 |
315 |
|
Returns |
99 |
9 |
271 |
12 |
24 |
118 |
268 |
|
Repeats |
1 |
0 |
4 |
0 |
0 |
4 |
1 |
|
Participants 1876 |
127 |
15 |
320 |
28 |
28 |
142 |
316 |
|
Returns |
98 |
8 |
276 |
16 |
26 |
121 |
269 |
|
Repeats |
0 |
2 |
0 |
0 |
0 |
1 |
4 |
|
Participants 1877 |
127 |
15 |
321 |
27 |
29 |
143 |
318 |
|
Returns |
99 |
9 |
272 |
14 |
25 |
121 |
271 |
|
Repeats |
1 |
0 |
2 |
0 |
1 |
5 |
1 |
|
Participants 2004 |
128 |
15 |
323 |
27 |
30 |
142 |
321 |
|
Returns |
99 |
10 |
279 |
15 |
27 |
120 |
277 |
|
Repeats |
0 |
0 |
1 |
0 |
0 |
4 |
0 |
|
Participants 2005 |
130 |
15 |
324 |
26 |
30 |
144 |
322 |
|
Returns |
98 |
9 |
277 |
13 |
25 |
117 |
270 |
|
Repeats |
0 |
0 |
5 |
0 |
1 |
4 |
0 |
|
Participants 2006 |
130 |
16 |
324 |
27 |
30 |
145 |
324 |
|
Returns |
101 |
11 |
272 |
15 |
28 |
120 |
277 |
|
Repeats |
0 |
0 |
9 |
0 |
0 |
1 |
0 |
Method performance
Mean Scores have been calculated for each distribution and each
antibiotic. To view the results for
each antibiotic click on the appropriate link that leads to an excel
spreadsheet. The worksheet labels are
shown in bold below.
·
Averages analysed by method (AB Method Performance)
·
Averages analysed by sub-method (AB Mean Submethods)
·
Overall Mean Scores (AB Mean all Methods)
Once again, it must be remembered that where the numbers of participants are low, comparisons should be made with caution. This is even more important when comparing mean scores than
it is to method CV%s. One poor
performer in a small group will have considerably more impact on mean score
than it will in a large group.
Table links:
Table 3a: Method codes used in the tables
|
Manufacturer |
Machine/ Method |
Method Code |
Manufacturer |
Machine/ Method |
Method Code |
|
Abbott |
TDx/FLx/
Axsym |
TDX |
Bio-assay |
Gram –ve |
GMNEG |
|
Abbott |
Architect |
ARCH |
Bio-assay |
Gram +ve |
GMPOS |
|
Bayer |
Technicon |
TECH
|
Bio-assay |
Yeast |
YEAST |
|
Bayer |
ADVIA
Centaur |
CENTA/ADVIA |
Launch |
Quantex
bio-kit |
BKT |
|
Beckman |
Coulter |
BECKM |
Dade |
immunoassay |
DADE |
|
Behring |
Opus |
OPUS |
Various |
High
performance Liquid chromatography |
HPLC |
|
Behring |
Emit |
EMIT |
Olympus Diagnostics |
AU400/600/640 2700/5400 |
OLMP |
|
Behring |
ACA PETINA |
PETINA |
Roche
Diagnostics |
immunoassay |
ROCHE |
Table 3b: Immunoassay sub-method codes used in the
tables
|
Manufacturer/ Machine |
Reagent |
Code |
Manufacturer/ Machine |
Reagent |
Code |
|
Abbott
Axysm |
Axsym |
AXM |
Roche |
Polarisation- flouroimmuno assay |
PFIA |
|
TDx/FLx |
Bio-stat |
BIO |
|
Kinetic interaction of microparticles |
KIMS |
|
|
Normal kit |
NK |
Bayer |
|
|
|
|
Sigma kit |
SIG |
Centaur |
ADVIA |
ADVIA |
|
Architect |
Architect |
ARCH |
|
|
|
|
Berhring |
|
|
|
|
|
|
Autoanalyser
(e.g. Cobas Bio) |
EMIT |
AA |
|
|
|
|
Wet manual (e.g. Syva) |
EMIT |
WM |
|
|
|
Other codes:
Reagent used not stated – NS
Table 4 Poor
Performers
Two 6-monthly summaries.
Laboratory numbers have been removed and replaced with letters. The same coding
system is used for both months but each summary contains the results for
different laboratories.
Distribution
1874.
Return date:
26/9/06
|
LAB |
ANAL |
METHOD |
SMETH |
COUNTRY |
TYPE |
MEAN+2SD |
SCORE |
|
A |
TOB |
BIOS |
PFIA |
UK |
NHS |
+1437.9 |
-1 |
|
B |
VANC |
BIOS |
PFIA |
UK |
NHS |
+102.7 |
-1 |
|
C |
VANC |
BIOS |
PFIA |
UK |
NHPH |
+91.0 |
0 |
|
D |
TEIC |
BIOS |
PFIA |
UK |
NHS |
+72.7 |
0 |
|
E |
GENT |
ABBT |
ARCH |
UK |
NHS |
+53.8 |
0 |
|
F |
GENT |
BIOS |
PFIA |
UK |
NHS |
+555.6 |
-1 |
|
G |
VANC |
BIOS |
PFIA |
UK |
NHS |
+94.6 |
0 |
|
H |
TOB |
EMIT |
NK |
UK |
NHS |
+93.6 |
0 |
|
I |
GENT |
TDX |
NK |
UK |
NHS |
+58.4 |
0 |
|
J |
TOB |
BIOS |
PFIA |
UK |
NHS |
+108.9 |
-1 |
|
K |
GENT |
BIOS |
PFIA |
UK |
NHS |
+139.2 |
-1 |
Distribution
2006
Return date:
27/3/06
|
LAB |
ANAL |
METHOD |
SMETH |
COUNTRY |
TYPE |
MEAN+2SD |
SCORE |
|
A |
GENT |
BKT |
NK |
UK |
NHS |
+54.3 |
0 |
|
B |
TOB |
BIOS |
SER |
UK |
PHL |
+51.0 |
0 |
|
C |
VANC |
ABBO |
AXM |
UK |
NHS |
+53.3 |
0 |
|
D |
GENT |
TDX |
PFIA |
UK |
NHS |
+55.4 |
0 |
|
E |
VANC |
BIOS |
SER |
UK |
NHS |
+50.2 |
0 |
|
F |
VANC |
BIOS |
SER |
UK |
NHS |
+56.8 |
0 |
|
G |
TOB |
BIOS |
SER |
UK |
NHS |
+51.9 |
0 |
|
H |
TOB |
BIOS |
SER |
UK |
NHS |
+54.1 |
0 |
|
I |
TEIC |
BIOS |
SER |
UK |
NHS |
+62.7 |
0 |
|
J |
GENT |
ROCHE |
PFIA |
UK |
NHS |
+149.0 |
-1 |
|
K |
TOB |
ROCHE |
PFIA |
UK |
NHS |
+134.8 |
-1 |
|
L |
VANC |
ROCHE |
PFIA |
UK |
NHS |
+129.2 |
-1 |